Johnson & Johnson (NYSE:JNJ) on Tuesday reported third-quarter 2026 results that beat Wall Street estimates. 25 billion.
Growth was driven by oncology treatments Darzalex, Carvykti, Tecvayli, Rybrevant/Lazcluze and Erleada. However, declining Stelara sales reduced growth by approximately 690 basis points.
S. The company said it is taking steps to improve performance while remaining confident in MedTech’s long-term prospects.
36 per share. The deals are also expected to weigh on 2026 adjusted earnings by 64 cents per share.
